MK2 is a therapeutic target for high-risk multiple myeloma

Chunyan Gu; Haibo Cheng; Hongbao Yang; Yong Bian; Yaohui Wang; Yifen Zhang; Michael Pisano; Gang Hu; Ye Yang

doi:10.3324/haematol.2017.182121

MK2 is a therapeutic target for high-risk multiple myeloma

Haematologica. 2021 Jun 1;106(6):1774-1777. doi: 10.3324/haematol.2017.182121.

Authors

Chunyan Gu¹, Haibo Cheng², Hongbao Yang³, Yong Bian⁴, Yaohui Wang⁵, Yifen Zhang⁵, Michael Pisano¹, Gang Hu⁶, Ye Yang⁷

Affiliations

¹ Department of Pathology, School of Medicine, University of Iowa, Iowa City, USA.
² The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China.
³ China Pharmaceutical University, Nanjing, China.
⁴ Laboratory Animal Center, Nanjing University of Chinese Medicine, Nanjing, China.
⁵ Department of Pathology, The First Affiliated Hospital of Nanjing University of Chinese Medicine.
⁶ School of Medicine and Life Sciences, Nanjing University of Chinese Medicine.
⁷ Nanjing University of Chinese Medicine, Nanjing, China.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Intracellular Signaling Peptides and Proteins
Multiple Myeloma* / drug therapy
Multiple Myeloma* / genetics
Protein Serine-Threonine Kinases

Substances

Intracellular Signaling Peptides and Proteins
Protein Serine-Threonine Kinases

Grants and funding

Funding: this work was supported by National Natural Science Foundation of China 81770220, 81600177, 81670200, 81500166 (to CG & YY); National key research and development program-precision medicine sub-program 2016YFC0905900 (to YY); The 2016 outstanding youth fund of Jiangsu Province BK20160048 (to YY); Natural Science Foundation of Jiangsu Province BK20161041, 16KJB310009 (to CG); The Priority Academic Program Development of Jiangsu Higher Education Institutions for Chinese Medicine.